First randomized trial of remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed

Treatment with the antiviral drug remdesivir does not speed recovery from COVID-19 compared with placebo in hospitalized patients who are critically ill, according to the first randomized trial of its kind involving 237 adults from 10 hospitals in Wuhan, China.

from Top Health News -- ScienceDaily https://ift.tt/2yaINPy